ID   REV_EIAVY               Reviewed;         165 AA.
AC   P20919;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   02-DEC-2020, entry version 70.
DE   RecName: Full=Protein Rev;
DE   AltName: Full=3'-ORF protein;
GN   Name=rev;
OS   Equine infectious anemia virus (strain Wyoming) (EIAV).
OC   Viruses; Riboviria; Pararnavirae; Artverviricota; Revtraviricetes;
OC   Ortervirales; Retroviridae; Orthoretrovirinae; Lentivirus.
OX   NCBI_TaxID=11672;
OH   NCBI_TaxID=9793; Equus asinus (Donkey) (Equus africanus asinus).
OH   NCBI_TaxID=9796; Equus caballus (Horse).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=2158694; DOI=10.1016/0042-6822(90)90254-o;
RA   Noiman S., Gazit A., Tori O., Sherman L., Miki T., Tronick S.R., Yaniv A.;
RT   "Identification of sequences encoding the equine infectious anemia virus
RT   tat gene.";
RL   Virology 176:280-288(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=2164593; DOI=10.1128/jvi.64.8.3716-3725.1990;
RA   Stephens R.M., Derse D., Rice N.R.;
RT   "Cloning and characterization of cDNAs encoding equine infectious anemia
RT   virus tat and putative Rev proteins.";
RL   J. Virol. 64:3716-3725(1990).
RN   [3]
RP   NUCLEAR EXPORT SIGNAL.
RX   PubMed=8230455; DOI=10.1128/jvi.67.12.7317-7323.1993;
RA   Fridell R.A., Partin K.M., Carpenter S., Cullen B.R.;
RT   "Identification of the activation domain of equine infectious anemia virus
RT   rev.";
RL   J. Virol. 67:7317-7323(1993).
RN   [4]
RP   NUCLEAR EXPORT SIGNAL.
RX   PubMed=8642662; DOI=10.1128/jvi.70.4.2350-2359.1996;
RA   Meyer B.E., Meinkoth J.L., Malim M.H.;
RT   "Nuclear transport of human immunodeficiency virus type 1, visna virus, and
RT   equine infectious anemia virus Rev proteins: identification of a family of
RT   transferable nuclear export signals.";
RL   J. Virol. 70:2350-2359(1996).
RN   [5]
RP   CHARACTERIZATION, RNA-BINDING, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   LYS-159; ARG-160; ARG-161; ARG-162 AND LYS-163.
RX   PubMed=16571801; DOI=10.1128/jvi.80.8.3844-3852.2006;
RA   Lee J.-H., Murphy S.C., Belshan M., Sparks W.O., Wannemuehler Y., Liu S.,
RA   Hope T.J., Dobbs D., Carpenter S.;
RT   "Characterization of functional domains of equine infectious anemia virus
RT   Rev suggests a bipartite RNA-binding domain.";
RL   J. Virol. 80:3844-3852(2006).
CC   -!- FUNCTION: Escorts unspliced or incompletely spliced viral pre-mRNAs
CC       (late transcripts) out of the nucleus of infected cells. These pre-
CC       mRNAs carry two recognition sequences that function as Rev responsive
CC       element (RRE), that are not present in fully spliced viral mRNAs (early
CC       transcripts). This function is essential since most viral proteins are
CC       translated from unspliced or partially spliced pre-mRNAs which cannot
CC       exit the nucleus by the pathway used by fully processed cellular mRNAs
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homomultimer; when bound to the RRE. Multimeric assembly is
CC       essential for activity (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Host nucleus, host nucleolus
CC       {ECO:0000269|PubMed:16571801}. Host cytoplasm
CC       {ECO:0000269|PubMed:16571801}. Note=The presence of both nuclear import
CC       and nuclear export signals leads to continuous shuttling between the
CC       nucleus and cytoplasm. {ECO:0000305}.
CC   -!- DOMAIN: The bipartite RNA-binding motif binds to the RREs present in
CC       incompletely spliced viral pre-mRNAs. It consists of a central region,
CC       and a C-terminal region that also contains the NLS which mediates
CC       nuclear localization. These overlapping functions prevent Rev bound to
CC       RRE from undesirable return to the nucleus. When Rev binds the RRE, the
CC       NLS becomes masked while the NES remains accessible.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA43027.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M36592; AAB02404.1; -; Genomic_RNA.
DR   EMBL; M54797; AAA43027.1; ALT_INIT; Genomic_RNA.
DR   PIR; B46357; ASLJ22.
DR   SMR; P20919; -.
DR   ELM; P20919; -.
DR   GO; GO:0030430; C:host cell cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0044196; C:host cell nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0019031; C:viral envelope; IEA:InterPro.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0051028; P:mRNA transport; IEA:UniProtKB-KW.
DR   InterPro; IPR021311; EIAV_Rev.
DR   InterPro; IPR001361; Gp90_EIAV.
DR   Pfam; PF00971; EIAV_GP90; 1.
DR   Pfam; PF11129; EIAV_Rev; 1.
PE   1: Evidence at protein level;
KW   Coiled coil; Host cytoplasm; Host nucleus; mRNA transport; RNA-binding;
KW   Transport.
FT   CHAIN           1..165
FT                   /note="Protein Rev"
FT                   /id="PRO_0000085478"
FT   REGION          57..130
FT                   /note="RNA-binding (RRE)"
FT   REGION          144..165
FT                   /note="RNA-binding (RRE)"
FT   COILED          1..26
FT                   /evidence="ECO:0000255"
FT   MOTIF           32..55
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000305"
FT   MOTIF           159..163
FT                   /note="Nuclear localization signal"
FT   MUTAGEN         159
FT                   /note="K->A: Complete loss of nuclear import; when
FT                   associated with A-160."
FT                   /evidence="ECO:0000269|PubMed:16571801"
FT   MUTAGEN         160
FT                   /note="R->A: Complete loss of nuclear import; when
FT                   associated with A-159 or A-161."
FT                   /evidence="ECO:0000269|PubMed:16571801"
FT   MUTAGEN         161
FT                   /note="R->A: Complete loss of nuclear import; when
FT                   associated with A-160 or A-162."
FT                   /evidence="ECO:0000269|PubMed:16571801"
FT   MUTAGEN         162
FT                   /note="R->A: Complete loss of nuclear import; when
FT                   associated with A-161 or A-163."
FT                   /evidence="ECO:0000269|PubMed:16571801"
FT   MUTAGEN         163
FT                   /note="K->A: Complete loss of nuclear import; when
FT                   associated with A-162."
FT                   /evidence="ECO:0000269|PubMed:16571801"
FT   CONFLICT        30
FT                   /note="K -> I (in Ref. 2)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        59
FT                   /note="C -> Y (in Ref. 2; AAA43027)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        88
FT                   /note="T -> A (in Ref. 2; AAA43027)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        114
FT                   /note="R -> Q (in Ref. 2; AAA43027)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   165 AA;  19810 MW;  04FDEB0830888F36 CRC64;
     MAESKEARDQ EMNLKEESKE EKRRNDWWKK DPQGPLESDQ WCRVLRQSLP EEKIPSQTCI
     ARRHLGPGPT QHTPSRRDRW IRGQILQTEV LQERLEWRIR GVQQAAKELG EVNRGIWREL
     YFREDQRGDF SAWGGYQRAQ ERLWGEQSSP RVLRPGDSKR RRKHL
//
